Chemours Q1 net loss widens to $29 million; net sales rise 1% to $1.4 billion
Chemours reported a first quarter 2026 net loss attributable to Chemours of $29 million, or $0.19 per diluted share, versus a $5 million loss, or $0.03 per share, a year earlier, while net sales rose 1% to $1.4 billion. Adjusted EPS fell to $0.05 from $0.13, but adjusted EBITDA edged up to $169 million from $166 million. The company kept its full-year 2026 adjusted EBITDA outlook of $800 million to $900 million and said it expects net leverage below 3.8x by the end of 2026.
Key points
- Net loss of $29 million ($0.19 per diluted share) vs. $5 million ($0.03) in Q1 2025, driven by higher financing costs from a recent debt offering and higher SG&A
- Net sales of $1,381 million, up 1%; Thermal & Specialized Solutions sales rose 22% to $568 million, while Titanium Technologies fell 6% and Advanced Performance Materials fell 17%
- Second quarter 2026 outlook calls for adjusted EBITDA of $220 million to $250 million; full-year 2026 adjusted EBITDA is $800 million to $900 million
- Received about $287 million in net proceeds from the April 2026 sale of nine Kuan Yin land parcels and paid down €140 million of term loans
The filing
Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.